Breast intraductal proliferative lesion
MONDO:0004007A group of non-invasive epithelial proliferations that occur in the ductal system of the breast. The vast majority of cases arise in the terminal ductal lobular units. This category includes atypical ductal hyperplasia, usual ductal hyperplasia, flat epithelial atypia, and ductal carcinoma in situ. There is an increased risk for subsequent development of invasive breast carcinoma.
Also known as: DIN, ductal intraepithelial neoplasia, intraductal proliferative lesion, intraductal proliferative lesion of the breast, mammary intraepithelial neoplasia, ductal type
1594 clinical trials for this condition and its sub-types, 8 tagged with Breast intraductal proliferative lesion itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Breast intraductal proliferative lesion
-
Ductal breast carcinoma in situ 152 trials
1 sub-type
-
Flat ductal epithelial atypia 3 trials
-
Usual ductal breast hyperplasia 0 trials
-
Surgery-free breast cancer treatment tested in new trial
Disease control Not yet recruitingThis study is testing whether people with certain non-invasive or early breast conditions (like ductal carcinoma in situ) can safely skip surgery and instead take hormone-blocking medication. The goal is to see if this approach keeps cancer from coming back over five years. The t…
Sponsor: Jeong Eon Lee • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a 'Baby Dose' of hormone pills prevent breast cancer?
Prevention Not yet recruitingThis study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC